HRP20020652A2 - Use of il-18 inhibitors - Google Patents

Use of il-18 inhibitors Download PDF

Info

Publication number
HRP20020652A2
HRP20020652A2 HRP20020652A HRP20020652A2 HR P20020652 A2 HRP20020652 A2 HR P20020652A2 HR P20020652 A HRP20020652 A HR P20020652A HR P20020652 A2 HRP20020652 A2 HR P20020652A2
Authority
HR
Croatia
Prior art keywords
inhibitor
use according
disease
production
treatment
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Yolande Chvatchko
Charles Dinarello
Christine Plater-Zyberk
Santer Van Deventer
Menachem Rubinstein
Daniela Novick
Soo-Hyun Kim
Original Assignee
Applied Research Systems
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems, Yeda Res & Dev filed Critical Applied Research Systems
Publication of HRP20020652A2 publication Critical patent/HRP20020652A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HRP20020652 2000-02-21 2001-02-20 Use of il-18 inhibitors HRP20020652A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00103590 2000-02-21
EP00103597 2000-02-21
EP00121651 2000-10-04
EP00125633 2000-11-23
PCT/EP2001/001867 WO2001062285A1 (en) 2000-02-21 2001-02-20 Use of il-18 inhibitors

Publications (1)

Publication Number Publication Date
HRP20020652A2 true HRP20020652A2 (en) 2004-12-31

Family

ID=27439934

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20020652 HRP20020652A2 (en) 2000-02-21 2001-02-20 Use of il-18 inhibitors

Country Status (30)

Country Link
US (1) US20030157094A1 (cs)
EP (1) EP1257292B1 (cs)
JP (1) JP4744763B2 (cs)
KR (3) KR20070087256A (cs)
CN (1) CN1322897C (cs)
AT (1) ATE506959T1 (cs)
AU (2) AU4063601A (cs)
BG (1) BG66134B1 (cs)
BR (1) BR0108514A (cs)
CA (2) CA2683009C (cs)
CY (1) CY1111687T1 (cs)
CZ (1) CZ304485B6 (cs)
DE (1) DE60144514D1 (cs)
DK (1) DK1257292T3 (cs)
EA (1) EA005583B1 (cs)
EE (1) EE05423B1 (cs)
HR (1) HRP20020652A2 (cs)
HU (1) HU227752B1 (cs)
IL (2) IL151388A0 (cs)
ME (1) ME00546B (cs)
MX (1) MXPA02008079A (cs)
NO (1) NO331971B1 (cs)
NZ (3) NZ535299A (cs)
PL (1) PL206549B1 (cs)
PT (1) PT1257292E (cs)
RS (1) RS51737B (cs)
SI (1) SI1257292T1 (cs)
SK (1) SK288032B6 (cs)
TR (2) TR200502508T2 (cs)
WO (1) WO2001062285A1 (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
TR200502508T2 (tr) * 2000-02-21 2007-04-24 Applied Research Systems Ar� Holding N.V. IL-18 İnhibitörlerinin kullanımı.
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
IL158866A0 (en) * 2001-05-16 2004-05-12 Yeda Res & Dev Use of il-18 inhibitors for the treatment or prevention of sepsis
WO2003045400A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
WO2004064713A2 (en) * 2003-01-20 2004-08-05 Vib Vzw The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors
US7491803B2 (en) 2003-04-30 2009-02-17 Japan Science & Technology Agency Human anti-human interleukin-18 antibody, fragment thereof and method for using same
WO2005047906A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
WO2006003927A1 (ja) 2004-06-30 2006-01-12 Atsuo Sekiyama 非炎症性ストレス応答の指標剤およびその利用
DK1808446T3 (da) * 2004-07-16 2012-05-14 Atsuo Sekiyama IL-18-receptor-antagonist og farmaceutisk sammensætning indeholdende antagonisten
SI1885753T1 (sl) 2005-06-03 2011-12-30 Ares Trading Sa Proizvodnja rekombinantnega il-18 vezavnega proteina
US8217152B2 (en) 2005-06-10 2012-07-10 Ares Trading S.A. Process for the purification of IL-18 binding protein
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
SG172625A1 (en) 2006-05-25 2011-07-28 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
EP3978526A1 (en) 2013-09-05 2022-04-06 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases
JP7274259B2 (ja) 2015-03-05 2023-05-16 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体
CN106109497A (zh) * 2016-07-25 2016-11-16 深圳爱生再生医学科技有限公司 治疗肝硬化的干细胞制剂
CN106834449B (zh) * 2017-01-10 2019-04-30 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
CN112236453A (zh) * 2018-06-14 2021-01-15 波尔多大学 使用白细胞介素-1抑制剂治疗胎盘慢性组织细胞绒毛间质炎
WO2023286694A1 (ja) 2021-07-13 2023-01-19 国立大学法人東海国立大学機構 炎症性腸疾患を治療するための医薬組成物
CN117647645B (zh) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
PT936923E (pt) * 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology Supressao de tnfalfa e il-12 em terapia
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
JP4026923B2 (ja) * 1997-03-12 2007-12-26 株式会社林原生物化学研究所 ポリペプチド
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
TR200502508T2 (tr) * 2000-02-21 2007-04-24 Applied Research Systems Ar� Holding N.V. IL-18 İnhibitörlerinin kullanımı.
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
YU60402A (sh) 2005-09-19
SK288032B6 (sk) 2012-12-03
SI1257292T1 (sl) 2011-08-31
NZ546294A (en) 2008-02-29
CN1404400A (zh) 2003-03-19
WO2001062285A1 (en) 2001-08-30
EE200200463A (et) 2003-12-15
CA2399298A1 (en) 2001-08-30
KR20070087256A (ko) 2007-08-27
NO20023962L (no) 2002-08-20
KR20020086540A (ko) 2002-11-18
HU227752B1 (en) 2012-02-28
EA005583B1 (ru) 2005-04-28
BR0108514A (pt) 2002-12-17
PT1257292E (pt) 2011-07-05
EE05423B1 (et) 2011-06-15
JP2003523403A (ja) 2003-08-05
NZ535299A (en) 2006-06-30
KR20070057282A (ko) 2007-06-04
NZ520122A (en) 2005-04-29
PL357554A1 (en) 2004-07-26
DK1257292T3 (da) 2011-07-18
CA2683009C (en) 2014-09-23
PL206549B1 (pl) 2010-08-31
JP4744763B2 (ja) 2011-08-10
BG66134B1 (bg) 2011-06-30
RS51737B (sr) 2011-10-31
TR200202030T2 (tr) 2003-01-21
MXPA02008079A (es) 2003-02-27
EA200200890A1 (ru) 2003-02-27
BG107018A (bg) 2003-09-30
AU2001240636B2 (en) 2005-10-13
IL151388A0 (en) 2003-04-10
CN1322897C (zh) 2007-06-27
NO20023962D0 (no) 2002-08-20
EP1257292B1 (en) 2011-04-27
AU2001240636B8 (en) 2005-11-03
AU4063601A (en) 2001-09-03
NO331971B1 (no) 2012-05-14
CZ20022843A3 (cs) 2003-02-12
SK12082002A3 (sk) 2003-05-02
CA2683009A1 (en) 2001-08-30
US20030157094A1 (en) 2003-08-21
EP1257292A1 (en) 2002-11-20
ATE506959T1 (de) 2011-05-15
CZ304485B6 (cs) 2014-05-28
ME00546B (me) 2011-10-10
DE60144514D1 (de) 2011-06-09
HK1051965A1 (en) 2003-08-29
TR200502508T2 (tr) 2007-04-24
CA2399298C (en) 2014-04-15
HUP0300061A3 (en) 2005-09-28
IL151388A (en) 2009-09-01
CY1111687T1 (el) 2015-10-07
HUP0300061A2 (hu) 2003-04-28

Similar Documents

Publication Publication Date Title
AU2001240636B2 (en) Use of il-18 inhibitors
EP1425028B1 (en) Use of il-18 inhibitors for the treatement or prevention of sepsis
AU2001240636A1 (en) Use of IL-18 inhibitors
US7696154B2 (en) Methods for treating interleukin-18 mediated disorders with interleukin-18 binding proteins
US20100254941A1 (en) Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US20090074710A1 (en) Method of treatment using a cytokine able to bind il-18bp to inhibit the activity of a second cytokine
ES2365600T3 (es) Uso de inhibidores de il-18.
HK1051965B (en) Use of il-18 inhibitors

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20040114

Year of fee payment: 4

A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: MERCK SERONO SA, CH

ODBI Application refused